Maia van Kan
YOU?
Author Swipe
View article: A higher throughput assay for quantification of melphalan-induced DNA damage in peripheral blood mononuclear cells
A higher throughput assay for quantification of melphalan-induced DNA damage in peripheral blood mononuclear cells Open
Inter-individual differences in DNA adduct formation and repair influence the response to melphalan treatment, however, further clinical investigation of this variability requires a logistically feasible and reproducible bioassay. Our impr…
View article: The importance of both <i>CYP2C19</i> and <i>CYP2B6</i> germline variations in cyclophosphamide pharmacokinetics and clinical outcomes
The importance of both <i>CYP2C19</i> and <i>CYP2B6</i> germline variations in cyclophosphamide pharmacokinetics and clinical outcomes Open
Cyclophosphamide is an alkylating agent used in the treatment of solid and haematological malignancies and as an immunosuppressive agent. As a prodrug, it is dependent on bioactivation to the active phosphoramide mustard metabolite to elic…
View article: P111 Developmental pharmacogenetics of CYP2D6 in Chinese children: loratadine as a probe drug
P111 Developmental pharmacogenetics of CYP2D6 in Chinese children: loratadine as a probe drug Open
Background Although the understanding of CYP2D6 developmental pharmacogenetics in children has made great progress, the current findings are mainly focused on Caucasian children. Given the clear ethnicity difference of CYP2D6 pharmacogenet…
View article: O02 Developmental pharmacogenetics of SLCO2B1 on montelukast pharmacokinetics in chinese children
O02 Developmental pharmacogenetics of SLCO2B1 on montelukast pharmacokinetics in chinese children Open
Background Montelukast, a potent orally selective leukotriene-receptor antagonist, inhibits the action of cysteinyl-leukotriene in patients with asthma.Although pharmacokinetic studies of montelukast have been reported in Caucasian adults …